<DOC>
	<DOCNO>NCT02319135</DOCNO>
	<brief_summary>The hypothesis replacement standard fludarabine cytarabine base therapy azacytidine could result improvement RFS OS rate experimental arm . To fulfill medical need frail elderly population , improvement term atileukemic efficacy azacytidine experimental arm attain without increase therapy-related toxicity decrease patient QoL .</brief_summary>
	<brief_title>Azacytidine ( Vidaza® ) Versus Fludarabine Cytarabine ( Fluga Scheme ) Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>This multicenter , randomize 1:1 , open , national level , Phase III clinical trial . This study conduct 3 phase different duration : 1 . Selection phase ( 14 day signature inform consent ) : inform consent review inclusion exclusion criterion perform relevant assessment . 2 . Treatment Phase ( start treatment end cycle 9 ) : Induction phase ( 3 cycle ) consolidation phase ( cycle 4-9 ) . Study visit treatment weekly induction phase ( first 3 cycle ) every 2 week end consolidation phase . 3 . Follow-up phase : monthly monitoring perform patient complete minimum 2 year start treatment , whether continue receive azacitidine cycle Mini-Fluga accord protocol . Following 24 month , follow-up carry least quarterly . Patients suffer disease progression relapse disease , early withdrawn due reason specify protocol followed-up survival end study death patient , whichever come first .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Having voluntarily give informed consent perform test part routine care patient . 2 . Age great equal 65 . 3 . Morphological diagnosis nonpromyelocytic AML accord WHO criterion . 4 . Newly diagnose AML . 5 . ECOG performance status &lt; 4 . 6 . Ability willingness comply schedule study visit . 1 . Genetic diagnosis acute promyelocytic leukemia . 2 . Patients AML secondary myelodysplastic syndrome ( MDS ) chronic myeloproloferative syndrome previously treat antileukemic agent ( hypomethylating standard chemotherapy ) . Treatment hydroxyurea prior randomization allow . 3 . Serum creatinine ≥ 250 mmol / l ( ≥ 2.5 mg/dL ) ( unless attribute AML ) . 4 . Bilirubin , alkaline phosphatase ALT &gt; 5 time value upper limit normal ( unless attribute AML ) . 5 . Presence active and/or non control pathology different AML severe lifethreatening , investigator 's opinion , prevents subject participation study . 6 . Other active concomitant malignancy whose remission less one year screen day ( except carcinoma situ ) . 7 . Presence psychiatric illness medical condition , investigator 's opinion , prevents subject participation study . 8 . Life expectancy less X month . 9 . Inability patient legal representative understand voluntarily sign informed consent form .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
</DOC>